Top in allergy/asthma: Updates on epinephrine nasal spray, dupilumab
Click Here to Manage Email Alerts
Responses to epinephrine nasal spray were comparable to those from injected epinephrine, researchers said.
The EpiPen had the fastest time to maximum plasma concentration compared with neffy and manual injection, but study results suggest the spray may be a safe and effective option for treating type I allergic reactions, including anaphylaxis.
It was the top story in allergy/asthma last week.
The second top story was about how children with asthma who are treated with dupilumab experienced fewer severe exacerbations regardless of prior exacerbation history.
Read these and more top stories in allergy/asthma below:
Epinephrine nasal spray outcomes comparable with injected delivery
Pharmacokinetic and pharmacodynamic responses to a nasal epinephrine spray were comparable with responses to injected epinephrine, according to a study published in The Journal of Allergy and Clinical Immunology. Brian Bizik, MS, PA-C, DFAAPA, and Jason Linde, MA, weighed in with their perspectives. Read more.
Dupilumab reduces corticosteroid burdens among children with asthma
Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster presented at the CHEST Annual Meeting. Read more.
Q&A: Managing risks of air pollution for people with asthma
High levels of ozone can be particularly harmful to people with asthma, and it turns out that local pollution may actually be generated from other areas. Read more.
Clinically significant respiratory disease associated with childhood wheeze
Clinically significant respiratory disease was significantly associated with childhood wheeze in a low-resource, nonindustrialized setting, according to a study published in Clinical and Translational Allergy. Read more.
Patients with both asthma, eosinophilic esophagitis experience earlier hospital visits
Patients with both eosinophilic esophagitis and asthma present to the hospital at an earlier age than those patients who only have EoE, researchers reported. Read more.